Medically reviewed by Isabel Casimiro, MD, PhDMedically reviewed by Isabel Casimiro, MD, PhD Immunoglobulin A nephropathy (known as IgA nephropathy or Berger's disease) is a rare kidney disease ...

Investigators systematically evaluate the efficacy differences of existing treatment regimens for IgA nephropathy.

One study found that after 10 years, IgA nephropathy came back in 19% of those who had a kidney transplant. About 4 out of 10 (40%) transplanted kidneys in people with IgA nephrology eventually fail.

For more information about IgA nephropathy and the role of APRIL, consider signing up to receive additional news and insights about IgA nephropathy at igancascade.com. October 2024 21US24EUP0096 ...

Purespring Therapeutics has received approval for its UK clinical trial application (CTA) for a Phase I/II trial of its lead ...

EP: 3. Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines EP: 4. Diagnosing IgA Nephropathy EP: 5. Signs and Symptoms of IgA Nephropathy EP: 6.

EP: 3. Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines EP: 4. Diagnosing IgA Nephropathy EP: 5. Signs and Symptoms of IgA Nephropathy EP: 6.

IgA nephropathy can be challenging, but a support system makes it easier to manage. Learn how to take steps to stay connected to your community when dealing with this disease.

Cite this: Looking Back at an Early Patient Encounter and the Changing Treatment Landscape in IgA Nephropathy - Medscape - March 05, 2025.

In this video, Ali Poyan Mehr, MD, Regional Director of the Glomerular Disease Program at Kaiser Permanente Northern California, discusses the major risk factors for IgA nephropathy.

NephCure, a nonprofit organization focused on rare, protein-spilling kidney diseases, announced IgA Nephropathy Awareness Day, Sept. 26, to promote early diagnosis and treatment of the disease ...

Pietro A. Canetta, MD, recounts how, as a young nephrologist at Columbia University, he was encouraged by a mentor to give a talk on IgA nephropathy, a topic that at the time had limited research ...